All In MedTech

FDA Clearance Tracker · P140020

BRACANALYSIS CDX

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Dec 19, 2014 (this decision)Source: openFDAMethods & limitations

PMAFirst of its product code

The decision

FDA number
P140020
Device name
BRACANALYSIS CDX
Applicant location
Salt Lake Cit, UT
Received
Sep 24, 2014
Decided
Dec 19, 2014
Decision
Approved
Expedited review
Yes, flagged as expedited in FDA's record.
Supplements
25 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code PJG

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE BRACANALYSIS CDX. THIS DEVICE IS INDICATED AS FOLLOWS: BRACANALYSIS CDX IS AN IN VITRO DIAGNOSTIC DEVICE INTENDED FOR THE QUALITATIVE DETECTION AND CLASSIFICATION OF VARIANTS IN THE PROTEIN CODING REGIONS AND INTRON/EXON BOUNDARIES OF THE BRCA1 AND BRCA2 GENES USING GENOMIC DNA OBTAINED FROM WHOLE BLOOD SPECIMENS COLLECTED IN EDTA. SINGLE NUCLEOTIDE VARIANTS AND SMALL INSERTIONS AND DELETIONS (INDELS) ARE IDENTIFIED BY POLYMERASE CHAIN REACTION (PCR) AND SANGER SEQUENCING. LARGE DELETIONS AND DUPLICATIONS IN BRCA1 AND BRCA2 ARE DETECTED USING MULTIPLEX PCR. RESULTS OF THE TEST ARE USED AS AN AID IN IDENTIFYING OVARIAN CANCER PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA VARIANTS ELIGIBLE FOR TREATMENT WITH LYNPARZA (OLAPARIB). THIS ASSAY IS FOR PROFESSIONAL USE ONLY AND IS TO BE PERFORMED ONLY AT MYRIAD GENETIC LABORATORIES, A SINGLE LABORATORY SITE LOCATED AT 320 WAKARA WAY, SALT LAKE CITY, UT 84108.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • This is the earliest decision in FDA's data under product code PJG (Cancer-related germline gene mutation detection system).
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Myriad Genetic Laboratories

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.